Background: Rates of amyloid-β (Aβ) accumulation have been characterized across the
cognitively normal to typical Alzheimer's dementia spectrum, but little is known about Aβ …

Blood-based biomarkers could prove useful to predict Alzheimer's disease core pathologies
in advance of clinical symptoms. Implementation of such biomarkers requires a solid …

INTRODUCTION Alzheimer's disease (AD) trial participants are often screened for eligibility
by brain amyloid positron emission tomography/cerebrospinal fluid (PET/CSF), which is …

Brain autopsy and biomarker studies indicate that the pathology of Alzheimer's disease (AD)
is initiated at least 10–20 years before clinical symptoms. This provides a window of …

Alzheimer's disease (AD) is the most common cause of dementia and affects a large portion
of the elderly population worldwide. Currently, a diagnosis of AD depends on the clinical …

Blood-based biomarkers have been extensively evaluated for their diagnostic potential in
Alzheimer's disease. However, their relative prognostic and monitoring capabilities for …

Abstract Background In Alzheimer's disease (AD), plasma amyloid beta (Aβ) 1‐42 and
phosphorylated tau (p‐tau) predict high amyloid status from Aβ positron emission …

The temporal evolutions and relative orderings of Alzheimer disease biomarkers, including
CSF amyloid-β42 (Aβ42), Aβ40, total tau (Tau) and phosphorylated tau181 (pTau181) …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …

In Alzheimer's disease (AD), the cerebral pathological changes begin many years before the
clinical manifestation of the disease. Biomarkers for AD, such as the cerebrospinal fluid …